Lornoxicam complex, lornoxicam-berberine cocrystal, preparation method and application thereof

Through the complex or eutectic of lonoxicam and berberine, the problems of lonoxicam insoluble and short half-life in gastric juice are solved, the dissolution rate and absorption effect are improved, and the sustained release effect of eutectics is extended The efficacy time of the drug is significantly improved the absorption of berberine hydrochloride.

CN117003769BActive Publication Date: 2024-11-22NINGBO INST OF MATERIALS TECH & ENG CHINESE ACAD OF SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310849852.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-11
Publication Date
2024-11-22
Estimated Expiration
2043-07-11

AI Technical Summary

Technical Problem

Lonoxicam is insoluble in gastric juice, resulting in a prolonged analgesic effect time and a short half-life in the body. It requires frequent medication, which increases the risk of adverse reactions; berberine hydrochloride has poor water solubility and is not absorbed by oral administration, which affects its clinical application.

Method used

Provides a complex or eutectic of lonoxicam and berberine, which is connected through non-covalent bonds or hydrogen bonds to form a lonoxicam-berberine co-crystal, improving its dissolution rate and oral absorption effect in gastric juice. , prolong the efficacy time.

Benefits of technology

It significantly improves the dissolution rate of lonoxicam in gastric juice, shortens the onset of analgesic effect, and delays the release effect in intestinal fluid, prolongs the efficacy time, and improves the intestinal absorption of berberine hydrochloride, improving The half-life and absorption effect of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117003769B_ABST
    Figure CN117003769B_ABST
Patent Text Reader

Abstract

The present application provides a lornoxicam complex, a lornoxicam-berberine cocrystal, and a preparation method and application thereof. The lornoxicam-berberine cocrystal comprises lornoxicam and berberine connected by hydrogen bonds. The lornoxicam-berberine cocrystal provided in the present application increases the dissolution rate of lornoxicam in simulated gastric juice, helps to shorten the analgesic onset time of lornoxicam, and delays its dissolution in simulated intestinal juice, which helps to prolong the half-life of lornoxicam; and the lornoxicam-berberine cocrystal also significantly increases the intestinal permeability of berberine, which helps to improve the absorption of berberine hydrochloride in the intestine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of medical technology, and specifically relates to a lornoxicam complex, a lornoxicam-berberine cocrystal, and a preparation method and application thereof. Background Art

[0002] Lornoxicam, chemical name is 6-chloro-4-hydroxy-2-methyl-3-(2-pyridinecarbamoyl)-2H thieno[2,3-e]-1,2-thiazine-1,1-dioxide, is a non-steroidal anti-inflammatory drug. Because it can suppress the activity of two isomers of cyclooxygenase, COX I and COXII, and then suppress prostaglandin synthesis, it has played a stronger analgesic and anti-inflammatory effect, can be used for treating multiple types of pain such as multiple acute postoperative pain, moderate and severe acute cancer pain clinically, can also be used for treating osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, it can significantly reduce the rest pain score, joint tenderness index and joint swelling index of osteoarthritis patients. But lornoxicam is hardly dissolved in gastric juice, causing its analgesic onset time to be extended, and its half-life in vivo is shorter, clinical oral lornoxicam tablets need to take medicine multiple times at least one day, and each medication multiple tablets have brought inconvenience to clinical patients. In addition, frequent medication can easily lead to large fluctuations in the blood concentration of lornoxicam, increasing the risk of adverse reactions. Therefore, how to improve the dissolution of lornoxicam in gastric juice and improve its analgesic effect is one of the problems that need to be solved in this field.

[0003]

[0004] Berberine hydrochloride, also known as berberine hydrochloride, is an isoquinoline alkaloid extracted from Copti and Berberis species. It has antibacterial, anti-inflammatory, analgesic, antioxidant and anti-tumor activities. According to literature reports, berberine hydrochloride relieves pain caused by diabetes and chemotherapy-induced neuropathy and sciatic nerve injury by downregulating transient receptor potential vanilloid 1, inhibiting NF-xB and regulating μ and δ opioid receptors. In addition, it can also inhibit inflammatory markers tumor necrosis factor-a, interleukin-6 and IL-1β, as well as prostaglandin E2, inducible nitric oxide synthase and COX II, and exert a variety of anti-inflammatory and analgesic activities. However, berberine hydrochloride has poor water solubility and is not absorbed after oral administration, which affects its clinical application.

[0005] Summary of the invention

[0006] To solve all or part of the above problems, this application provides the following technical solutions:

[0007] One of the purposes of the present application is to provide a lornoxicam complex, which comprises at least lornoxicam and berberine.

[0008] In some embodiments, the molar ratio of lornoxicam to berberine in the lornoxicam complex is 1:(0.5-1.5).

[0009] In some preferred embodiments, the molar ratio of lornoxicam to berberine is 1:1.

[0010] In some embodiments, lornoxicam and berberine in the lornoxicam complex are linked by a non-covalent bond.

[0011] In some embodiments, the lornoxicam in the lornoxicam complex is in crystal form II.

[0012] In some embodiments, the lornoxicam complex is crystalline or amorphous. The crystalline form is, for example, completely crystalline, partially crystalline, polymorphic or co-crystalline.

[0013] The second purpose of the present application is to provide a lornoxicam-berberine cocrystal, wherein the lornoxicam-berberine cocrystal comprises lornoxicam and berberine connected by non-covalent bonds, and the lornoxicam-berberine cocrystal is a monoclinic system, and the unit cell parameters are as follows:

[0014] Space group = P21 / c,

[0015] Unit cell length a=7.2240(13), b=25.536(5), c=17.045(3),

[0016] Unit cell angle (°) α = 90, β = 101.617 (6), γ = 90,

[0017] Volume = 3079.8 (10),

[0018] Z = 4,

[0019] R1=0.0409;wR2=0.1006.

[0020] In some embodiments, the X-ray diffraction pattern of the lornoxicam-berberine cocrystal has characteristic peaks at diffraction angles 2θ of approximately 6.3°, 6.9°, 8.7°, 12.7°, 13.8°, 18.0°, 18.6°, 20.8°, 25.1° and 35.5°.

[0021] In some embodiments, the X-ray diffraction pattern of the lornoxicam-berberine cocrystal has characteristic peaks at diffraction angles 2θ of approximately 6.3°, 6.9°, 8.7°, 11.2°, 12.7°, 13.8°, 14.1°, 15.0°, 18.0°, 18.5°, 20.2°, 20.8°, 22.8°, 24.3°, 25.1°, 25.8°, 28.2°, 28.7°, 30.3° and 35.5°.

[0022] In some embodiments, lornoxicam and berberine in the lornoxicam-berberine co-crystal are linked by hydrogen bonds.

[0023] In some embodiments, the molar ratio of lornoxicam to berberine in the lornoxicam-berberine cocrystal is 1:(0.5-1.5). Preferably, the molar ratio of lornoxicam to berberine in the lornoxicam-berberine cocrystal is 1:1.

[0024] In some preferred embodiments, the basic structural unit of the lornoxicam-berberine cocrystal consists of 4 lornoxicam molecules and 4 berberine molecules, wherein one lornoxicam molecule is connected to one berberine molecule by a hydrogen bond.

[0025] In some embodiments, the melting point of the lornoxicam-berberine eutectic is 216-225°C.

[0026] The third object of the present application is to provide a method for preparing the lornoxicam-berberine cocrystal described in the above technical scheme, the preparation method comprising: precipitating crystals from a mixture containing at least lornoxicam and berberine hydrochloride to obtain the lornoxicam-berberine cocrystal.

[0027] In some embodiments, the preparation method specifically includes: dissolving lornoxicam, berberine hydrochloride and a strong base in an organic solvent to obtain a mixed solution, and volatilizing and crystallizing the mixed solution to obtain the lornoxicam-berberine cocrystal.

[0028] In some embodiments, the strong base includes at least one of sodium hydroxide, potassium hydroxide, tetramethylammonium hydroxide and tetrabutylammonium hydroxide.

[0029] In some embodiments, the organic solvent includes at least one of dichloromethane, ethanol, methanol and acetone.

[0030] In some embodiments, the volatilization temperature of the mixed solution during volatilization and crystallization is 20-30°C.

[0031] In some embodiments, in the mixed solution, the molar ratio of the strong base to lornoxicam is 1:(0.5-1.5). Preferably, the molar ratio of the strong base to lornoxicam is 1:1.

[0032] In the mixed solution, the molar ratio of lornoxicam to berberine hydrochloride is 1:(0.5-1.5). Preferably, the molar ratio of lornoxicam to berberine hydrochloride is 1:1.

[0033] In some embodiments, the preparation method of the lornoxicam-berberine cocrystal includes: dissolving lornoxicam and berberine hydrochloride in an alkaline organic solvent to obtain a suspension, stirring, filtering and drying the suspension to obtain the lornoxicam-berberine cocrystal.

[0034] In some embodiments, the alkaline organic solvent includes at least one of sodium ethoxide, sodium methoxide, ethanol and methanol.

[0035] In some embodiments, the stirring temperature is 20-30° C., and the stirring speed is 100-400 rpm.

[0036] In some embodiments, the stirring time is 5 to 10 days. Preferably, the stirring time is 7 days.

[0037] In some embodiments, in the suspension, the molar ratio of lornoxicam to berberine hydrochloride is 1:(0.5-1.5). Preferably, the molar ratio of lornoxicam to berberine hydrochloride is 1:1.

[0038] The fourth object of the present application is to provide the use of the lornoxicam complex in the above technical solution or the lornoxicam-berberine cocrystal in the above technical solution in the preparation of a drug, wherein the drug has at least anti-inflammatory or analgesic function. Preferably, it has at least one of antibacterial, anti-inflammatory, analgesic, antioxidant and anti-tumor functions. The drug can be, for example, an oral drug. Preferably, the drug is a sustained-release oral drug. More preferably, the drug is a lornoxicam sustained-release preparation or a berberine hydrochloride oral preparation.

[0039] The fifth object of the present application is to provide a pharmaceutical composition, which comprises the lornoxicam complex described in the above technical scheme or the lornoxicam-berberine cocrystal described in the above technical scheme.

[0040] The sixth object of the present application is to provide a lornoxicam sustained-release preparation, which comprises the lornoxicam complex described in the above technical scheme or the lornoxicam-berberine cocrystal described in the above technical scheme.

[0041] The seventh object of the present application is to provide a berberine hydrochloride oral preparation, which comprises the lornoxicam complex described in the above technical scheme or the lornoxicam-berberine cocrystal described in the above technical scheme.

[0042] The eighth object of the present application is to provide the use of the lornoxicam complex described in the above technical scheme, the lornoxicam-berberine cocrystal described in the above technical scheme, the pharmaceutical composition described in the above technical scheme, the lornoxicam sustained-release preparation described in the above technical scheme or the berberine hydrochloride oral preparation described in the above technical scheme in the preparation of anti-inflammatory drugs or analgesics.

[0043] Compared with the prior art, this application has at least the following beneficial effects:

[0044] (1) The present application provides a lornoxicam complex, which has good sustained-release effect and oral absorption effect compared with simple lornoxicam and simple berberine hydrochloride, and significantly improves the problem of short half-life of simple lornoxicam and the defect of simple berberine hydrochloride that it is not absorbed orally. Therefore, the lornoxicam complex has good application prospects and market prospects as an oral drug raw material;

[0045] (2) The present application provides a lornoxicam-berberine cocrystal. Compared with simple lornoxicam, the dissolution rate of the lornoxicam-berberine cocrystal in simulated gastric fluid is significantly improved, and the cumulative dissolution amount in 2 hours is twice that of simple lornoxicam. Using the lornoxicam-berberine cocrystal as a drug raw material helps to shorten the onset time of drug analgesia;

[0046] (3) The lornoxicam and berberine in the lornoxicam-berberine co-crystal provided by the present application have a sustained-release effect on each other, that is, in simulated intestinal fluid and water, the dissolution rates of lornoxicam and berberine in the co-crystal are significantly slowed down, and the sustained-release effect of lornoxicam and berberine reaches more than 24 hours. The lornoxicam-berberine co-crystal as a drug raw material can significantly prolong the drug effect time;

[0047] (4) Compared with berberine hydrochloride alone, the apparent permeability coefficient of lornoxicam-berberine cocrystal in Caco-2 monolayer cells for 2 hours is 5 times that of berberine hydrochloride alone, indicating that the lornoxicam-berberine cocrystal provided in the present application can significantly improve the absorption of berberine hydrochloride in the intestine without affecting the absorption of lornoxicam in the intestine;

[0048] (5) The lornoxicam-berberine cocrystal provided in the present application has good crystal stability and no crystal transformation occurs after being stored for three months at a temperature of 40°C and a humidity of 75% RH;

[0049] (6) The present application provides a simple and economical preparation method of the lornoxicam-berberine cocrystal, which is suitable for large-scale and industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0051] Figure 1 is a single crystal structure diagram of lornoxicam-berberine cocrystal in one embodiment of the present application;

[0052] Figure 2 is a powder X-ray diffraction pattern of lornoxicam-berberine cocrystal in one embodiment of the present application;

[0053] Figure 3 is a differential scanning calorimetry (DSC) diagram of the lornoxicam-berberine cocrystal in one embodiment of the present application;

[0054] Figure 4 is a thermogravimetric analysis (TGA) diagram of lornoxicam-berberine cocrystal in one embodiment of the present application;

[0055] Figure 5 This is the XRD pattern of the lornoxicam-berberine cocrystal in one embodiment of the present application after being stored at a temperature of 40° C. and a humidity of 75% for 90 days;

[0056] Figure 6 This is a dissolution diagram of lornoxicam powder of lornoxicam-berberine cocrystal and pure lornoxicam in simulated gastric fluid in an embodiment of the present application;

[0057] Figure 7 This is a dissolution diagram of berberine powder of lornoxicam-berberine cocrystal and pure berberine in simulated gastric fluid in an embodiment of the present application;

[0058] Figure 8 This is a dissolution diagram of lornoxicam powder of lornoxicam-berberine cocrystal and pure lornoxicam in simulated intestinal fluid in an embodiment of the present application;

[0059] Fig. 9 This is a dissolution diagram of berberine powder of lornoxicam-berberine cocrystal and pure berberine in simulated intestinal fluid in one embodiment of the present application. DETAILED DESCRIPTION

[0060] The technical solution of the present application is described in detail below in conjunction with specific embodiments so that those skilled in the art can better understand and implement the technical solution of the present application. The specific functional details disclosed herein should not be interpreted as being restrictive, but only as the basis for the claims and as a representative basis for teaching those skilled in the art to adopt the present application in different ways in any appropriate detailed embodiment.

[0061] The detection instruments and instrument parameter settings used in the embodiments of the present application are as follows:

[0062] (1) Powder X-ray diffraction

[0063] Instrument: Bruker D8 Advance X-ray Diffractometer

[0064] Target: Cu-Kα target

[0065] wavelength:

[0066] Tube voltage: 40kV

[0067] Tube current: 40mA

[0068] Step size: 0.02°

[0069] Scanning speed: 4° / min

[0070] Scanning range: 5°-40°

[0071] (2) Differential Scanning Calorimetry (DSC)

[0072] Instrument: TA 2500 differential scanning calorimeter

[0073] Heating rate: 10℃ / min

[0074] Temperature range: 30-300℃

[0075] (3) Thermogravimetric analysis (TGA)

[0076] Instrument: NETZSCH TG209C Thermogravimetric Analyzer

[0077] Heating rate: 10℃ / min

[0078] Temperature range: 30-300℃

[0079] (4) Single crystal X-ray diffraction

[0080] Instrument: BrukerAPEX-II CCD single crystal diffractometer

[0081] Target: Mo-Kα

[0082] Wavelength: λ = 0.71073nm

[0083] Scanning temperature: 170K

[0084] Scanning range: 2.441°-26.281°

[0085] Example 1

[0086] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0087] Accurately weigh 0.3718g of lornoxicam, 0.4438g of berberine hydrochloride and 0.0401g of sodium hydroxide and place them in a beaker, add 50mL of ethanol and 5mL of dichloromethane, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 25°C to obtain a crystalline product after 7 days, and then filter it, place the filtered product in a vacuum drying oven, and dry it at 25°C for 24h to obtain a lornoxicam-berberine cocrystal, the single crystal structure of which is shown in the figure below: Figure 1 shown.

[0088] The prepared lornoxicam-berberine cocrystal was characterized by powder X-ray diffraction, differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). The powder X-ray diffraction analysis results are as follows: Figure 2 As shown, according to Figure 2 It can be seen that the lornoxicam-berberine cocrystal prepared in this example has characteristic peaks at diffraction angles 2θ of approximately 6.3°, 6.9°, 8.7°, 11.2°, 12.7°, 13.8°, 14.1°, 15.0°, 18.0°, 18.5°, 20.2°, 20.8°, 22.8°, 24.3°, 25.1°, 25.8°, 28.2°, 28.7°, 30.3° and 35.5°; the differential scanning calorimetry analysis results are as follows Figure 3 The thermogravimetric analysis results are shown in Figure 4 shown.

[0089] Example 2

[0090] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0091] Accurately weigh 0.3718 g of lornoxicam, 0.4438 g of berberine hydrochloride and 0.0401 g of sodium hydroxide and place them in a beaker, add 50 mL of methanol, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 30°C to obtain a crystalline product after 5 days, and then filter it. Place the product obtained by filtration in a vacuum drying oven and dry it at 25°C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0092] Example 3

[0093] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0094] Accurately weigh 0.3718 g of lornoxicam, 0.4438 g of berberine hydrochloride and 0.0506 g of sodium hydroxide and place them in a beaker, add 50 mL of methanol and 5 mL of dichloromethane, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 20°C to obtain a crystalline product after 6 days, and then filter it, place the filtered product in a vacuum drying oven, and dry it at 25°C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0095] Example 4

[0096] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0097] Accurately weigh 0.3718 g of lornoxicam, 0.4438 g of berberine hydrochloride and 0.0912 g of tetramethylammonium hydroxide and place them in a beaker, add 50 mL of methanol and 50 mL of acetone, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 20°C to obtain a crystalline product after 4 days, and then filter it, place the product obtained by filtration in a vacuum drying oven, and dry it at 25°C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0098] Example 5

[0099] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0100] Accurately weigh 0.3718 g of lornoxicam, 0.4438 g of berberine hydrochloride and 0.0912 g of tetramethylammonium hydroxide and place them in a beaker, add 50 mL of ethanol and 30 mL of acetone, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 20°C to obtain a crystalline product after 6 days, and then filter it, place the product obtained by filtration in a vacuum drying oven, and dry it at 25°C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0101] Example 6

[0102] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0103] Accurately weigh 0.3718 g of lornoxicam, 0.4438 g of berberine hydrochloride and 0.2595 g of tetrabutylammonium hydroxide and place them in a beaker, add 50 mL of methanol and 30 mL of acetone, stir and ultrasonically dissolve, and then filter; slowly evaporate the solvent at 25°C to obtain a crystalline product after 4 days, and then filter it, place the filtered product in a vacuum drying oven, and dry it at 25°C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0104] Example 7

[0105] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0106] Accurately weigh 0.1859 g of lornoxicam and 0.2209 g of berberine hydrochloride and place them in a beaker, add 0.03 mL of sodium ethoxide and 2 mL of ethanol, stir magnetically at 25 ° C and 400 rpm for 7 days, then filter, and dry the filtered precipitate in a vacuum drying oven at 25 ° C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0107] Example 8

[0108] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0109] Accurately weigh 0.1859 g of lornoxicam and 0.2209 g of berberine hydrochloride and place them in a beaker, add 0.025 mL of sodium methoxide and 2 mL of methanol, stir magnetically at 20 ° C and 400 rpm for 7 days, then filter, and dry the filtered precipitate in a vacuum drying oven at 25 ° C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0110] Example 9

[0111] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0112] Accurately weigh 1.859 g of lornoxicam and 2.209 g of berberine hydrochloride and place them in a beaker, add 0.3 mL of sodium ethoxide and 30 mL of ethanol, stir magnetically at 30 ° C and 250 rpm for 7 days, then filter, and dry the filtered precipitate in a vacuum drying oven at 25 ° C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0113] Example 10

[0114] This embodiment provides a lornoxicam-berberine cocrystal and a preparation method thereof:

[0115] Accurately weigh 1.859 g of lornoxicam and 2.209 g of berberine hydrochloride and place them in a beaker, add 0.25 mL of sodium methoxide and 30 mL of methanol, stir magnetically at 25 ° C and 100 rpm for 10 days, then filter, and dry the filtered precipitate in a vacuum drying oven at 25 ° C for 24 hours to obtain lornoxicam-berberine cocrystal.

[0116] The lornoxicam-berberine cocrystals prepared in Examples 2-10 were characterized by powder X-ray diffraction, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA), and the results were basically consistent with those of the lornoxicam-berberine cocrystals prepared in Example 1.

[0117] The present application further tests or inspects the crystal stability, dissolution in simulated gastric fluid, dissolution in simulated intestinal fluid, toxicity to Caco-2 cells and apparent permeability coefficient of Caco-2 monolayer cells of the lornoxicam-berberine cocrystal prepared above. The test and inspection methods and results are as follows.

[0118] 1. Study on the crystal stability of lornoxicam-berberine cocrystal

[0119] The lornoxicam-berberine eutectic prepared in Example 1 was stored at 40°C and 75%RH for 90 days, and then subjected to XRD detection. The detection results are as follows: Figure 5 As shown. Figure 5 It can be seen that all diffraction peak angles of the lornoxicam-berberine cocrystal remain unchanged after being stored at 40°C and 75% RH for 90 days, indicating that the cocrystal has excellent thermal stability.

[0120] 2. Powder dissolution test in simulated gastric fluid

[0121] Take about 16 mg of lornoxicam-berberine cocrystal from an 80-mesh sieve. The dissolution test method is the second method (paddle method) of General Chapter 0931 of the 2015 edition of the Chinese Pharmacopoeia. The dissolution medium is simulated gastric fluid (pH 1.0 hydrochloric acid solution), the medium volume is 900 mL, the temperature is 37°C, and the rotation speed is 50 rpm. The sampling time was 5, 10, 15, 20, 30, 45, 60, 90, 120, 360, 480, 720, 960, 1200, 1440 min, the sampling volume was 5 mL, the sample was filtered through a 0.22 μm polyethersulfone aqueous phase filter, and detected by an Agilent (Agilent, 1260) high performance liquid phase system, using a ZORBAX SB-C18 (4.6×250 mm, 5 μm) chromatographic column, the mobile phase was an aqueous phase containing 0.05 M sodium dihydrogen phosphate and 0.05 M 1-heptane sulfonate (pH adjusted to 3.5)-acetonitrile = 60:40, the flow rate was 1 mL / min, the detection wavelength was 260 nm, the column temperature was 30 ° C, and the concentrations of lornoxicam and berberine were detected. The dissolution of lornoxicam in lornoxicam-berberine cocrystal is as follows Figure 6 As shown in FIG. 1 , the dissolution of berberine in the lornoxicam-berberine cocrystal is as follows Figure 7 shown.

[0122] At the same time, pure lornoxicam and pure berberine were used as controls, and the powder dissolution of pure lornoxicam and pure berberine in simulated gastric juice was tested under the same operation (i.e., only the sample in the above method was replaced with 80-mesh sieve lornoxicam 8 mg or 80-mesh sieve berberine 8 mg). The dissolution of pure lornoxicam was as follows Figure 6 As shown in Figure 2, the dissolution of pure berberine is as follows: Figure 7 shown.

[0123] Combined with reference Figure 6 and Figure 7 It can be seen that in the simulated gastric fluid environment, the dissolution rate of lornoxicam in lornoxicam-berberine cocrystal is significantly improved, and the cumulative dissolution amount in the first 2 hours is about twice that of pure lornoxicam. The significantly improved release rate of lornoxicam in the cocrystal helps to shorten the onset time of drug analgesia. The dissolution rate of berberine in lornoxicam-berberine cocrystal in the first hour is slightly higher than that of pure berberine hydrochloride, and the cumulative dissolution amount in the first 2 hours is almost equal to that of berberine, and 100% is dissolved in 24 hours.

[0124] 3. Powder dissolution test in simulated intestinal fluid

[0125] Take about 16 mg of lornoxicam berberine cocrystal through an 80-mesh sieve. The dissolution test method is the second method (paddle method) of General Rules 0931 of the 2015 edition of the Chinese Pharmacopoeia. The dissolution medium is simulated intestinal fluid (pH 6.8 phosphate buffer solution), the medium volume is 900 mL, the temperature is 37°C, and the rotation speed is 50 rpm. The sampling time was 5, 10, 15, 20, 30, 45, 60, 90, 120, 360, 480, 720, 960, 1200, 1440 min, the sampling volume was 5 mL, the sample was filtered through a 0.22 μm polyethersulfone aqueous phase filter, and detected by an Agilent (Agilent, 1260) high performance liquid phase system, using a ZORBAX SB-C18 (4.6×250 mm, 5 μm) chromatographic column, the mobile phase was an aqueous phase containing 0.05 M sodium dihydrogen phosphate and 0.05 M 1-heptane sulfonate (pH adjusted to 3.5)-acetonitrile = 60:40, the flow rate was 1 mL / min, the detection wavelength was 260 nm, the column temperature was 30 ° C, and the concentrations of lornoxicam and berberine were detected. The dissolution of lornoxicam in lornoxicam-berberine cocrystal is as follows Figure 8 As shown in FIG. 1 , the dissolution of berberine in the lornoxicam-berberine cocrystal is as follows Fig. 9 shown.

[0126] At the same time, pure lornoxicam and pure berberine hydrochloride were used as controls, and the powder dissolution test of pure lornoxicam and pure berberine in simulated intestinal fluid was tested under the same operation (i.e., only the sample in the above method was replaced with 80-mesh sieve lornoxicam 8 mg or 80-mesh sieve berberine 8 mg). The dissolution of pure lornoxicam was as follows Figure 8 As shown in Figure 2, the dissolution of pure berberine hydrochloride is as follows: Fig. 9 shown.

[0127] Combined with reference Figure 8 and Fig. 9It can be seen that in the simulated intestinal fluid environment, the dissolution rates of lornoxicam and berberine in the lornoxicam-berberine cocrystal are significantly slowed down. The dissolution of lornoxicam in the lornoxicam-berberine cocrystal in 24 hours is only 72%, and the dissolution of berberine in the cocrystal in 24 hours is only 82%, indicating that berberine has a sustained-release effect on lornoxicam in simulated intestinal fluid, and lornoxicam also has a sustained-release effect on berberine in simulated intestinal fluid. Therefore, using the cocrystal as a drug raw material can significantly prolong the efficacy time.

[0128] 4. Caco-2 cell toxicity test

[0129] Caco-2 cells were seeded in a standard 96-well plate at a density of 5000 cells / well. Lornoxicam, berberine hydrochloride and lornoxicam-berberine cocrystals were then dissolved in a mixed solution of DMEM containing 10% FBS and less than 1% DMSO (v / v), and then diluted with DMEM containing 10% FBS. After filtering through a microporous membrane (0.22 μm), the concentrations of lornoxicam and berberine hydrochloride were 0.0975, 0.195, 0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25 and 50 μg / ml, respectively, and the concentrations of lornoxicam berberine cocrystal were 0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50 and 100 ug / ml (containing 50 μg / ml lornoxicam and 50 μg / ml berberine). At the same time, a withering group (DMEM, CCK8, DMSO) and a control group (Caco-2 cells, DMEM, CCK8, DMSO) were set up as controls and treated with the solution for 4 hours. The cells were then incubated with CCK8 at 37°C for 24 hours, and the absorbance was measured at 450 nm using an enzyme reader. The cell survival rate was calculated as a percentage, and the results are shown in Table 1. The cell survival rate was calculated as follows:

[0130] Cell survival rate = (experimental group - apoptosis group) / (control group - apoptosis group)

[0131] Table 1 CCK8 OD value and cell survival rate of lornoxicam, berberine hydrochloride and cocrystal Caco-2 cells after 24 hours

[0132]

[0133] From the results in Table 1, it can be seen that within the concentration range of 0.195-25 μg / ml, lornoxicam, berberine hydrochloride and cocrystal solution showed insignificant cytotoxicity (cell viability greater than 88%). Therefore, lornoxicam, berberine hydrochloride and cocrystal solution at a concentration of 20 μg / ml were selected for in vitro permeability study.

[0134] 5. Apparent permeability coefficient of Caco-2 monolayer cells

[0135] Establishment of Transwell monolayer cell model: Caco-2 cells were seeded in a 12-well Transwell plate at a density of 1×10 5 Cells were cultured in a 37°C, 5% CO2 incubator for 21 days. The culture medium was changed every other day for the first 3 days and then changed every day. The resistance Teer value was measured using a Millicell cell resistance meter (Merck Millipore, Germany). According to literature reports, the resistance value is >400Ω·cm 2 This indicated that the Caco-2 monolayer cell model was established.

[0136] Sample preparation and administration: 4 mg of lornoxicam, 4 mg of berberine hydrochloride and 8 mg of lornoxicam-berberine cocrystal were accurately weighed and placed in 2 ml centrifuge tubes, and 1 ml of DMSO was added to dissolve the drugs. The DMSO solution was allowed to fully contact the inner wall of the centrifuge tube for 30 min. 5 μl of DMSO solution was added to 1 ml of D-Hank's solution and mixed to obtain a 20 μg / ml drug solution (DMSO content was 0.5%).

[0137] Before administration, wash the cells three times with D-Hank's solution preheated at 37°C, and place them in a 37°C incubator for 20 minutes for the last time. Carefully aspirate the upper liquid, add 0.5 ml of the test drug solution to the AP side (supply side), and add 1.0 mL of blank D-Hank's solution to the BL side (receiving side) as the receiving solution. Each sample is in triplicate and incubated in a constant temperature shaker (37°C, 40 rpm). Accurately aspirate 200 μl of liquid from the BL side at 120 minutes, centrifuge at 20°C and 12000 rpm for 10 minutes, take 100 μl of the supernatant, and determine the drug content using the chromatographic conditions in Example 11. Calculate the intestinal permeability coefficient Papp value according to the following equation.

[0138] Q=C i V

[0139]

[0140] In the above formula, Q is the cumulative transport amount, which represents the total amount of the compound appearing on the BL side (receiving side), dQ / dt is the cumulative transport amount per unit time, V is the volume of the BL side (receiving side), and C i is the drug concentration on the BL side (receiving side), C0 is the initial concentration of the drug on the AP side (donating side), and A is the surface area of ​​the polyester membrane on the 12-well Transwell plate. The apparent permeability coefficients of lornoxicam, berberine hydrochloride, and lornoxicam-berberine cocrystal in Caco-2 monolayer cells are shown in Table 2.

[0141] Table 2 Apparent permeability coefficients of lornoxicam, berberine hydrochloride, and lornoxicam-berberine cocrystal in Caco-2 monolayer cells

[0142] Grouping <![CDATA[P app (A→B)]]> Lornoxicam 1.46494E-05 Berberine Hydrochloride 8.81827E-07 Cocrystal-Lornoxigen 1.57796E-05 Cocrystal-berberine 4.36762E-06

[0143] From the results in Table 2, we can see that the Papp value of lornoxicam at 120 min is 1.46494×10 -5 , greater than 1.0×10 -5 , indicating that lornoxicam is a highly permeable drug. The Papp value of berberine hydrochloride is 8.81827×10 -7 , much less than 1.0×10 -5 , indicating that it is a low permeability drug. Compared with berberine hydrochloride, the Papp value of berberine in the cocrystal is significantly increased by 5 times, while not reducing the permeability of lornoxicam, indicating that lornoxicam-berberine cocrystal will significantly improve the absorption of berberine hydrochloride in the intestine, while not affecting the absorption of lornoxicam in the intestine.

[0144] 6. Crystal data and structural parameters of lornoxicam-berberine cocrystal

[0145] (1) The crystallographic data of lornoxicam-berberine cocrystal are shown in Table 3:

[0146] Table 3 Crystallographic data of lornoxicam-berberine cocrystal

[0147]

[0148]

[0149] (2) The main bond length data of lornoxicam-berberine cocrystal are shown in Table 4:

[0150] Table 4 Main bond length data of lornoxicam-berberine cocrystal

[0151]

[0152]

[0153] (3) The main bond angle data of lornoxicam-berberine cocrystal are shown in Table 5:

[0154] Table 5 Main bond angle data of lornoxicam-berberine cocrystal

[0155]

[0156]

[0157] In summary, the lornoxicam-berberine cocrystal provided in the present application improves the dissolution rate of lornoxicam in simulated gastric juice based on the good synergistic effect between lornoxicam and berberine, which helps to shorten the analgesic onset time of lornoxicam, and delays its dissolution in simulated intestinal juice, which helps to prolong the half-life of lornoxicam; and the lornoxicam-berberine cocrystal also significantly improves the intestinal permeability of berberine, which helps to improve the absorption of berberine hydrochloride in the intestine. The problem of prolonged analgesic onset time and short half-life caused by the difficulty of dissolving lornoxicam in gastric juice when used alone in the prior art is well solved, and the problem of berberine hydrochloride being difficult to absorb when used alone is well solved.

[0158] Moreover, the lornoxicam-berberine cocrystal provided by the present application has good crystal stability and low cytotoxicity, and thus has broad market application prospects. The present application further provides a preparation method of the lornoxicam-berberine cocrystal, which is simple, economical, and suitable for large-scale and industrial production.

[0159] The various aspects, embodiments, features and examples of the present application should be considered as illustrative in all aspects and are not intended to limit the present application, the scope of which is defined solely by the claims. Other embodiments, modifications and uses will be apparent to those skilled in the art without departing from the spirit and scope of the present application as claimed.

[0160] In addition, the applicant of this case also referred to the aforementioned embodiments and conducted experiments with other raw materials, process operations, and process conditions described in this specification, and obtained relatively ideal results.

[0161] Although the present application has been described with reference to illustrative embodiments, it will be understood by those skilled in the art that various other changes, omissions and / or additions may be made without departing from the spirit and scope of the present application and that the elements of the embodiments may be replaced by substantial equivalents. In addition, many modifications may be made without departing from the scope of the present application to adapt specific circumstances or materials to the teachings of the present application. Therefore, it is not intended herein to limit the present application to the disclosed specific embodiments for performing the present application, but it is intended that the present application will include all embodiments within the scope of the appended claims. In addition, unless specifically stated, any use of the terms first, second, etc. does not indicate any order or importance, but rather uses the terms first, second, etc. to distinguish one element from another element.

Claims

1. A lornoxicam-berberine cocrystal, Features: The lornoxicam-berberine cocrystal comprises lornoxicam and berberine connected by non-covalent bonds, and the lornoxicam-berberine cocrystal is a monoclinic system, and the unit cell parameters are as follows: Space group = P 21 / c, Unit cell length (Å) a = 7.2240 (13), b = 25.536 (5), c = 17.045 (3), Unit cell angle (°) α = 90, β = 101.617 (6), γ = 90, Volume = 3079.8(10), Z=4, R 1 =0.0409; wR 2 =0.1006。 2. The lornoxicam-berberine cocrystal according to claim 1, Features: In the X-ray diffraction pattern of the lornoxicam-berberine cocrystal, characteristic peaks are present at diffraction angles 2θ of approximately 6.3°, 6.9°, 8.7°, 12.7°, 13.8°, 18.0°, 18.6°, 20.8°, 25.1° and 35.5°.

3. The lornoxicam-berberine cocrystal according to claim 1, Features: In the X-ray diffraction pattern of the lornoxicam-berberine cocrystal, there are characteristic peaks at diffraction angles 2θ of approximately 6.3°, 6.9°, 8.7°, 11.2°, 12.7°, 13.8°, 14.1°, 15.0°, 18.0°, 18.5°, 20.2°, 20.8°, 22.8°, 24.3°, 25.1°, 25.8°, 28.2°, 28.7°, 30.3° and 35.5°.

4. The lornoxicam-berberine cocrystal according to claim 1, Features: The lornoxicam and berberine in the lornoxicam-berberine co-crystal are connected by hydrogen bonds.

5. The lornoxicam-berberine cocrystal according to claim 1, Features: The molar ratio of lornoxicam to berberine in the lornoxicam-berberine cocrystal is 1: (0.5~1.5).

6. The lornoxicam-berberine cocrystal according to claim 5, Features: The molar ratio of lornoxicam to berberine is 1:

1.

7. The lornoxicam-berberine cocrystal according to claim 6, Features: The basic structural unit of the lornoxicam-berberine cocrystal consists of four lornoxicam molecules and four berberine molecules, wherein one lornoxicam molecule is connected to one berberine molecule via a hydrogen bond.

8. The lornoxicam-berberine cocrystal according to claim 1, Features: The melting point of the lornoxicam-berberine eutectic is 216-225°C.

9. The method for preparing the lornoxicam-berberine cocrystal according to any one of claims 1 to 8, It is characterized in that include: A mixture containing at least lornoxicam and berberine hydrochloride is crystallized to obtain a lornoxicam-berberine cocrystal.

10. The method for preparing the lornoxicam-berberine cocrystal according to claim 9, It is characterized in that Specifically include: Lornoxicam, berberine hydrochloride and a strong base are dissolved in an organic solvent to obtain a mixed solution, and the mixed solution is volatilized and crystallized to obtain the lornoxicam-berberine cocrystal.

11. The method for preparing the lornoxicam-berberine cocrystal according to claim 10, Features: The strong base includes at least one of sodium hydroxide, potassium hydroxide, tetramethylammonium hydroxide and tetrabutylammonium hydroxide.

12. The method for preparing the lornoxicam-berberine cocrystal according to claim 10, Features: The organic solvent includes at least one of dichloromethane, ethanol, methanol and acetone.

13. The method for preparing the lornoxicam-berberine cocrystal according to claim 10, Features: The volatilization temperature of the mixed solution during volatilization and crystallization is 20-30°C.

14. The method for preparing the lornoxicam-berberine cocrystal according to claim 10, Features: In the mixed solution, the molar ratio of the strong base to lornoxicam is 1:(0.5-1.5).

15. The method for preparing the lornoxicam-berberine cocrystal according to claim 14, Features: The molar ratio of the strong base to lornoxicam is 1:

1.

16. The method for preparing the lornoxicam-berberine cocrystal according to claim 10, Features: In the mixed solution, the molar ratio of lornoxicam to berberine hydrochloride is 1: (0.5~1.5).

17. The method for preparing the lornoxicam-berberine cocrystal according to claim 16, Features: The molar ratio of lornoxicam to berberine hydrochloride is 1:

1.

18. The method for preparing the lornoxicam-berberine cocrystal according to claim 9, It is characterized in that Specifically include: Lornoxicam and berberine hydrochloride are dissolved in an alkaline organic solvent to obtain a suspension, and the suspension is stirred, filtered and dried to obtain a lornoxicam-berberine cocrystal.

19. The method for preparing the lornoxicam-berberine cocrystal according to claim 18, Features: The stirring temperature is 20-30°C, and the stirring speed is 100-400 rpm.

20. The method for preparing the lornoxicam-berberine cocrystal according to claim 18, Features: The stirring time is 5 to 10 days.

21. The method for preparing the lornoxicam-berberine cocrystal according to claim 20, Features: The stirring time is 7 days.

22. The method for preparing the lornoxicam-berberine cocrystal according to claim 18, Features: In the suspension, the molar ratio of lornoxicam to berberine hydrochloride is 1: (0.5~1.5).

23. The method for preparing the lornoxicam-berberine cocrystal according to claim 22, Features: The molar ratio of lornoxicam to berberine hydrochloride is 1:

1.

24. Use of the lornoxicam-berberine cocrystal according to any one of claims 1 to 8 in the preparation of a drug, wherein the drug has at least one of antibacterial, anti-inflammatory, analgesic, antioxidant and anti-tumor functions.

25. The use according to claim 24, Features: The medicine is an oral medicine.

26. The use according to claim 25, Features: The drug is a sustained-release oral drug.

27. The use according to claim 24, Features: The medicine is a lornoxicam sustained-release preparation or a berberine hydrochloride oral preparation.

28. A pharmaceutical composition, Features: The pharmaceutical composition comprises the lornoxicam-berberine cocrystal according to any one of claims 1 to 8.

29. A lornoxicam sustained-release preparation, Features: The lornoxicam sustained-release preparation comprises the lornoxicam-berberine cocrystal according to any one of claims 1 to 8.

30. A berberine hydrochloride oral preparation, Features: The berberine hydrochloride oral preparation comprises the lornoxicam-berberine cocrystal according to any one of claims 1 to 8.

31. Use of the lornoxicam-berberine cocrystal according to any one of claims 1 to 8, the pharmaceutical composition according to claim 28, the lornoxicam sustained-release preparation according to claim 29 or the berberine hydrochloride oral preparation according to claim 30 in the preparation of anti-inflammatory drugs or analgesics.